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ABSTRACT 
Recent advances in molecular engineering and synthetic biology have made it possible for biomolecular and cell-based therapies 
to provide highly specific disease treatment. However, both the ability to spatially target the action of such therapies, and their 
range of effects on the target tissue remain limited. Here we show that biomolecules and cells can be engineered to deliver potent 
mechanical effects at specific locations inside the body under the direction of focused ultrasound. This capability is based on gas 
vesicles, a unique class of air-filled protein nanostructures derived from buoyant photosynthetic microbes. We show that low-
frequency ultrasound can convert these nanoscale biomolecules into micron-scale cavitating bubbles, as demonstrated with 
acoustic measurements and ultrafast optical microscopy. This allows gas vesicles targeted to cell-surface receptors to serve as 
remotely detonated cell-killing agents. In addition, it allows cells genetically engineered to express gas vesicles to be triggered with 
ultrasound to lyse and release therapeutic payloads. We demonstrate these capabilities in vitro, in cellulo, and in vivo. This technology 
equips biomolecular and cellular therapeutics with unique capabilities for spatiotemporal control and mechanical action.
INTRODUCTION 
Targeted molecular and cellular therapeutics have 
revolutionized the treatment of diseases such as cancer by 
allowing therapy to be aimed more specifically at pathological 
cells and tissues. For example, antibodies have been used to 
deliver molecular warheads such as cytotoxic agents and 
radionuclides to tumors1. Meanwhile, engineered microbial 
and mammalian cells have provided therapeutic capabilities 
based on their ability to home to specific tissues2,3, express 
diagnostic3–5 or therapeutic6–8 proteins or carry out targeted 
cell killing9,10. However, both biomolecular and cell-based 
therapies are currently limited by a lack of mechanisms for 
external spatial and temporal control and a restricted 
repertoire of therapeutic actions11,12. Here we address these 
limitations by designing biomolecules and cells to act as seeds 
for acoustic inertial cavitation – the formation, growth and 
violent collapse of gas bubbles. This phenomenon is triggered 
remotely at specific locations using focused ultrasound, leading 
to strong local mechanical effects capable of killing target cells 
and actuating the release of genetically encoded therapeutic 
payloads.  
Our approach takes advantage of gas vesicles (GVs), 
a unique class of genetically encoded gas-filled protein 
nanostructures that were recently introduced as reporter genes 
for high-frequency ultrasound and magnetic resonance 
imaging (MRI)13–16. GVs comprise amphiphilic protein shells 
with typical cylindrical widths of 45–250 nm and lengths of 
100-600 nm17 that are permeable to gas but exclude water due
to their hydrophobic interior surface (Fig. 1a). In nature,
photosynthetic bacteria and archaea produce intracellular
GVs as a means to achieve cellular buoyancy18. Recently it was
discovered that GVs’ gas-filled interiors allow them to serve as
contrast agents for high-frequency diagnostic ultrasound and
MRI13,14,16,19–22. In addition, it was shown that engineered
multi-gene clusters encoding GVs can be heterologously
expressed in Escherichia coli and Salmonella typhimurium, two 
frequently used bacterial chasses for the development of cell-
based diagnostic and therapeutic agents15. However, the use of 
GVs and GV-expressing cells as therapeutic agents has not 
been investigated. 
 In this study, we hypothesized that at lower 
ultrasound frequencies GVs can serve as nuclei for the 
formation and cavitation of free bubbles, turning targeted and 
cell-expressed GVs into mechanical therapeutic warheads. We 
tested this fundamental hypothesis using acoustic spectroscopy 
and ultrafast optical microscopy, then asked whether GVs 
Figure 1 | Gas vesicles as nuclei for inertial cavitation.  
a, Schematic drawing of a GV. The GV’s amphiphilic protein shell 
encloses a stable, gas-filled structure. b, Representative transmission 
electron microscopy (TEM) images of intact (left) and collapsed (right) 
Anabaena flos-aquae GVs. c, Proposed mechanism of GV-seeded 
cavitation. An ultrasound (US) pulse with a positive pressure higher 
than the critical collapse pressure, Pcol, collapses the GV, resulting in 
the release of a nanoscale air bubble. The released nanobubble 
undergoes cavitation if the peak negative pressure of the US pulse 
reaches below the critical cavitation pressure, Pcav. Over several 
cycles, the nanobubble is converted into a micron-scale bubble, which 
can eventually undergo violent inertial cavitation. Scale bar 
represents 200 nm.  
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functionalized with targeting moieties can serve as ultrasound-
triggered cellular disruptors. In addition, we assessed the ability 
of engineered therapeutic bacteria expressing GVs to be 
triggered with ultrasound to lyse and release molecular 
payloads. Finally, we tested the ability of GV-seeded cavitation 
to take place in vivo in a mouse tumor xenograft. These 
experiments provide a proof of principle for ultrasound-
triggered inertial cavitation as a new capability in targeted 
molecular therapeutics and synthetic biology.   
RESULTS 
GVs act as seeds for bubble formation and cavitation 
Our hypothesis that GVs can nucleate bubbles for inertial 
cavitation arises from the fact that GVs collapse under applied 
acoustic pressure (Fig. 1b), releasing the air contained inside 
them to the surrounding media. The ability of such collapse to 
take place at specific pressure thresholds, defined by GVs’ 
DNA sequence and protein composition, has been used for 
background-subtracted molecular imaging13–15,19. Under most 
conditions, gas molecules released from collapsed GVs are 
expected to form nanoscale bubbles, which should dissolve 
within milliseconds due to Laplace pressure23. However, we 
hypothesized that at ultrasound frequencies in the sub-MHz 
range, these free bubbles could also serve as seeds for 
cavitation, a process in which bubbles expand and contract 
during the negative and positive phases of sound waves, 
respectively, and can grow in size through rectified gas 
diffusion and coalescence24. Such processes are favored at 
lower ultrasound frequencies and higher peak negative 
pressures. In addition, bubbles can be stabilized by the 
presence of hydrophobic surfaces25, such as the exposed 
interior of collapsed GV shells (Fig. 1b). We envisioned that 
positive pressure above GVs’ critical collapse threshold would 
break open the GVs to release gas nanobubbles, and that 
negative pressure would then cause these bubbles to grow. At 
relatively low ultrasound amplitudes, the resulting bubbles 
would undergo stable cavitation – a sustained periodic 
oscillation of gas bubble size. At relatively high amplitudes, the 
bubbles would undergo rapid growth and violent collapse in a 
process known as inertial cavitation, unleashing powerful 
mechanical effects26 (Fig. 1c). 
To test our hypothesis that GVs can seed bubble 
cavitation, we first performed acoustic measurements on GVs 
purified from Anabaena flos-aquae, looking for acoustic signatures 
of stable and inertial cavitation. While bubbles undergoing 
stable cavitation emit pressure waves at the transmitted 
frequency and its harmonics, those undergoing inertial 
cavitation emit pressure waves with broad spectral content. We 
performed acoustic spectroscopy on GV suspensions in a 
custom-built chamber with acoustically transparent polymer 
walls. Focused ultrasound (FUS) was applied with a focused 
single-element transducer, and emitted signals were recorded 
with an orthogonally positioned imaging transducer 
functioning as a passive cavitation detector (PCD) (Fig. 2a). 
Unless stated otherwise, GV were insonated at a frequency of 
0.67 MHz throughout this study, and the PCD transducer was 
a 128-element linear array with a center frequency of 18 MHz. 
We chose this insonation frequency due to its common use in 
therapeutic ultrasound. 
We observed both stable and inertial cavitation in GV 
suspensions exposed to FUS. Harmonic signals, indicative of 
stable cavitation, were clearly elicited when the GVs were 
Figure 2 | Purified GVs act as seeds for stable and inertial cavitation. a, Diagram of in vitro passive cavitation detection (PCD) 
setup used to measure the acoustic signatures of cavitation activity in response to focused ultrasound (FUS). b, Representative frequency spectra 
of backscattered signals from purified GVs (0.3 nM) insonated by a single US pulse at varying peak negative pressures (PNP), 30-cycles, 670 
kHz. C, Mean harmonic signal from GVs (0.3 nM), bovine serum albumin (BSA, matched in mg/mL to GVs concentration), and PBS as a 
function of PNP (n = 16 for GVs and n = 8 for BSA and PBS). d, Mean broadband signal from GVs, BSA, and PBS as a function of PNP 
(n=16 for GVs, n = 8 for BSA, and PBS. statistical analysis:  orange * - GVs vs. PBS, orange + - GVs vs. BSA, purple * - BSA vs. PBS). e, 
Average broadband measurements from GVs insonated with varying ultrasound pulse lengths (PNP = 0.6 MPa, n=12). f, Broadband signal 
from different concentrations of GVs insonated with a single 1.0 MPa pulse (n=5). Plots show mean ± SEM (c, d, e, f).  
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insonated at 0.2 MPa peak negative pressure (PNP) (Fig. 2b, 
c), while broadband spectral emissions, characteristic of 
inertial cavitation, were observed at higher pressure levels 
(Fig. 2b, d). These values were significantly higher than those 
recorded from buffer or solutions of bovine serum albumin 
(BSA), which served as a protein control. Broadband emissions 
increased moderately with the pulse length (Fig. 2e), and 
pulses with only 3 peak negative cycles were sufficient to 
produce signals 25 ± 0.7 dB above the noise floor, consistent 
with cavitation studies on other samples27,28. As expected, the 
measured broadband signal increased with GV concentration 
until reaching a peak at 0.3 nM (Fig. 1f), above which acoustic 
shadowing interfered with measurement (Supplementary 
Fig. 1). These results suggest that GVs are able to serve as 
nuclei for inertial cavitation at 0.67 MHz.  
Since GV are also used for ultrasound imaging, 
typically at frequencies of several MHz, we also measured 
cavitation responses at 3 MHz.  At this frequency inertial 
cavitation required much higher pressures (Supplementary 
Fig. 2a-b), consistent with the lower efficiency of free bubble 
cavitation at higher frequencies, as well as the increased 
pressure required to collapse GVs at frequencies above the gas 
permeation rate of their protein shell29. This result affirms the 
ability of GVs to be imaged safely using typical diagnostic 
parameters21,22 while serving as seeds for inertial cavitation at 
lower frequencies.  
To more directly visualize the process by which GVs 
nucleate the formation of cavitating bubbles, we imaged this 
process optically using an ultra-high frame rate camera, 
acquiring images at 5 million frames per second (Fig. 3a). The 
GVs were attached to acoustically transparent Mylar-
bottomed dishes using biotin and streptavidin. Before 
insonation, we observed a dark pattern indicative of intact GVs 
(Fig. 3b), whose gas interiors scatter visible light18,30. After 
ultrasound was applied and reached sufficient amplitude, this 
dark pattern suddenly disappeared, revealing GV collapse (1.4 
Figure 3 | Ultrafast optical imaging of GV-seeded bubble formation and cavitation. a, Schematic drawing of the high frame rate 
(HFR) camera setup enabling GV cavitation imaging at a frame rate of 5 MHz. b, HFR camera images immediately before GV collapse (left), 
immediately after GV collapse (middle), and after the formation of bubbles (right). c, Number of unique cavitation loci in biotinylated dishes 
with and without GVs, upon insonation with a single 1.4 MPa burst (p= 0.0411, n=6). FUS pulses with 30 cycles at 670 kHz were used unless 
otherwise stated. d, Representative high-speed camera frames showing every other maximum and minimum of bubble cavitation, preceded by 
GV collapse. e, Bubble growth rate, quantified as the temporal derivative of the normalized average inverted pixel intensity in (d) (left).  The 
plot on the right shows each maximum in the growth rate aligned to the phase offset from the time of GV collapse. f, Bubble size and phase 
offset from GV collapse analyzed from HFR images as in (e). g, Average phase offset for peak size and peak growth rate for three different 
regions of interest. Plots show mean ± SEM (c, g). Scale bar represents 20 µm (b). 
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– 1.8 μs, Fig. 3b and Supplementary Fig. 3). 2.4 µs later, 
we observed dark bubbles forming and cavitating inside the 
field of view (Fig. 3b, Supplementary Movie 1), and 
continuing to grow in the following cycles (Fig. 3d). 
Meanwhile, control dishes with biotin coating alone failed to 
show significant cavitation (Fig. 3c). We further analyzed the 
videos to track the temporal relationship between GV collapse 
and bubble cavitation. After forming, bubbles grew and shrank 
at the frequency of the ultrasound waves (Fig. 3d). By 
comparing the phase of the wave at which GVs disappear with 
the phase of maximal bubble growth rate, we could confirm 
that GVs collapse at the positive pressure peak, while maximal 
growth of the resulting bubbles occurs at the negative peak of 
the ultrasound cycle, π apart in phase (Fig. 3e), and bubble 
size peaks at 3/2 π, at the conclusion of rarefaction (Fig. 3f). 
Similar results were seen across bubbles (Fig. 3g). This data 
confirms the ability of GVs to nucleate bubble cavitation and 
supports the mechanistic model depicted in in Fig. 1c.  
 
Receptor-targeted GVs serve as acoustically 
detonated cellular disruptors 
After establishing that GVs can nucleate microscale bubbles, 
we investigated two applications of biomolecular cavitation: 
acoustically detonated killing of tumor cells with receptor-
targeted GVs and triggered cavitation of intracellular GVs in 
engineered bacteria, leading to cell lysis and release of a protein 
payload. To test the first application, we prepared GVs 
genetically engineered to display an RGD peptide on the C-
terminus of their outer shell protein, GvpC, thereby targeting 
them to αVβ₃ integrin receptors commonly overexpressed in 
tumors31. We incubated these nanostructures with U87 
glioblastoma cells cultured on Mylar film (Fig. 4, a-b). For 
visualization, the GVs were also chemically labeled with Alexa 
Fluor 488.  To monitor cellular disruption, the media was 
supplemented with propidium iodide (PI), a membrane-
impermeable fluorophore that becomes fluorescent upon 
entering disrupted cells and intercalating with nucleic acids. 
Prior to ultrasound exposure, there was negligible PI signal. 
 
Figure 4 | Molecularly-targeted GVs serve as ultrasound-triggered disruptors of mammalian cells. a, Schematic drawing of 
the fluorescent microscopy setup used for imaging of GV-mediated cell disruption. RGD-functionalized GVs were attached to U87 cells grown 
on Mylar-bottomed dishes. b, Bright field (BF) image of U87 cells, fluorescence images of GVs (green) and propidium iodide (PI, red), before 
the application of ultrasound. c, PI fluorescence 5, 60, or 300 sec after ultrasound exposure. d, Change in PI signal measured from individual 
cells (gray) and the average (red) before, during and after FUS application (represented by blue shading). e, Percentage of PI-positive cells 
following FUS exposure with and without GV attachment. (P = 0.0002 using a two-sided heteroscedastic t-test, n=4) f, HFR camera image 
showing the formation of bubbles during ultrasound application to cells treated with GVs. g, Number of unique cavitation loci observed in 
dishes containing U87 cells with and without GVs. (P < 0.0001, n=8). Bar plots show mean ± SEM (e, g). Scale bars represent 20 µm (b, c, f).  
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However, after insonation for 10 seconds, we observed gradual 
PI uptake in many cells throughout the field of view (Fig. 4, c-
d), as quantified relative to PI uptake after saponin treatment 
(Fig. 4e).  Ultrasound alone in the absence of GVs did not 
result in significant PI uptake. 
 To directly visualize the effect of ultrasound on GVs 
attached to U87 cells, we imaged the cells at 5 million frames 
per second. After the collapse of cell-attached GVs 
(Supplementary Fig. 4, a-b) we observed bubble formation 
and cavitation (Fig. 4f, Supplementary Fig. 4c, 
Supplementary Movie 2). The number of cavitation events 
in cells targeted with GVs was significantly greater than the 
number of random cavitation events in untreated cells (Fig. 
4g). The spatial heterogeneity of cavitation in the high-speed 
camera experiment (Fig. 4f, Supplementary Fig. 4c) was 
consistent with the clustering of PI-positive cells next to each 
other (Fig. 4c). Taken together, these results suggest that GVs 
can be used as targeted, acoustically triggered mechanical 
warheads for cellular disruption.  
 
Genetically expressed GVs enable cells to undergo 
inertial cavitation  
In addition to their use as purified agents, GVs can be 
expressed inside engineered cells, as shown recently in E. coli 
Nissle 1917 and S. typhimurium using a hybrid GV-encoding 
gene cluster15. We hypothesized that cells expressing GVs 
could be triggered to undergo intracellular bubble formation 
and cavitation under low frequency ultrasound, resulting in 
cellular lysis and the release of a co-expressed protein payload 
(Fig. 5a). To test this concept, we engineered a 14-gene 
operon combining GV-encoding genes GvpA–GvpU from the 
ARG1 gene  cluster15 with a gene encoding the luminescent 
NanoLuc protein as a model releasable payload (Fig. 5b). This 
construct was transformed into S. typhimurium SL1344, a strain 
used in several experimental bacterial therapies2,3. Since it was 
previously shown that ARG1 GVs have a relatively high 
collapse pressure15 we used a lower ultrasound frequency of 
300 kHz in these experiments to ensure efficient collapse of the 
heterologously expressed GVs at achievable pressure levels. 
To test whether the GV-expressing bacteria (Fig. 5c) 
could serve as sources of inertial cavitation, we measured 
broadband  acoustic emissions from cell suspensions exposed 
to FUS. In response to ultrasound pulses, the GV-expressing S. 
typhimurium emitted a high level of broadband  signals, 
increasing with the peak negative pressure (Fig. 5d). Similar 
activity was not observed in control cells expressing just 
NanoLuc. 
Next, we examined the lysis of GV-expressing cells in 
response to focused ultrasound and measured the release of 
their co-expressed protein payload. In an assay comparing the 
 
Figure 5 | GVs as genetically encoded seeds for cellular inertial cavitation and payload release. a, Proposed mechanism of 
intra-cellular GV-seeded cavitation and cell disruption. The collapse of GVs inside the cell creates a nanobubble, which cavitates, disrupts the 
cell membrane and releases cell contents, including an engineered payload. b, Genetic construct combining a hybrid gas vesicle gene cluster 
from A. flos-aquae and B. megaterium with the a NanoLuc luciferase (Lux) payload. c, Phase contrast microscopy image of S. typhimurium cells 
expressing the construct in (b). GVs appear inside the cells as white inclusions, while the rest of the cells appear black. d, Mean broadband 
emissions from NanoLuc-expressing cells (Lux, negative control) and cells co-expressing GVs and NanoLuc, at various pressure levels (p < 0.05, 
n = 8) e, Representative agar plates and average colony counts for Lux and Lux+GV cells exposed to ultrasound, normalized by the number 
of colonies from non-exposed control samples (p = 0.0002, n = 8 for Lux+GV and n = 6 for Lux). f, Bioluminescent signal in the media 
surrounding Lux or Lux+GV cells with and without exposure to ultrasound. The signal from each sample is normalized by the signal measured 
from the same cells after chemical lysis (two-way ANOVA analysis: percentage of variation attributed to the interaction is 9.6% with p=0.001, 
n = 6). Scale bar represents 15 μm (c).  
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number of colonies formed on agar plates by cells that were 
exposed to ultrasound to cells that were not, we found that 
significantly fewer colonies were produced by GV-expressing 
S. typhimurium cells following ultrasound exposure, compared to
the equivalent experiment with NanoLuc controls (Fig. 5e).
The bioluminescence of the media, corresponding to payload
release, was also significantly elevated in GV-expressing cells
exposed to ultrasound compared to controls (Fig. 5f). Taken
together, these results suggest that GV-expressing engineered
cells can serve as ultrasound-triggered cellular “explosives”,
releasing proteins into their surroundings in response to a
remote trigger.
GVs seed inertial cavitation in vivo 
After establishing GVs as biomolecular and cellular cavitation 
nuclei in vitro and in cellulo, we tested the ability of GVs to 
nucleate cavitation in vivo in a mouse tumor xenograft. We 
developed a 3D-printed holder to co-align the foci of both the 
focused transducer and the imaging transducer at the center of 
the tumor (Fig. 6a), with a needle guide incorporated to 
facilitate precise injections into the tumor core. This setup 
enabled us to perform ultrasound-guided ultrasound therapy 
experiments, in which we acquired images of the GVs inside 
the tumor and performed FUS treatment and PCD 
measurements at the injection site. Adult BALB/c mice were 
injected in the flanks with two MC26 tumors, one in each side. 
After the tumors reached diameters of 6-10 mm (Fig. 6b, left), 
we performed ultrasound-guided GV injections and FUS 
treatment. We injected one tumor in each mouse with purified 
GVs and the contralateral tumor with saline as a vehicle 
control. To facilitate GV imaging, we used GVs in which 
GvpC has been removed19, allowing them to produce non-
linear ultrasound contrast easily distinguishable from 
background using an amplitude modulation pulse sequence22 
(Fig. 6b, middle). PCD measurements acquired during FUS 
application, performed before and after the injection of saline 
or GVs, revealed strong broadband  signals representing 
inertial cavitation only from GV-injected tumors (Fig. 6, c-d). 
After FUS exposure, the image contrast from injected GVs 
disappeared, providing confirmation of their collapse (Fig. 6b, 
right). These results demonstrate that gas vesicles can serve as 
biomolecular cavitation nuclei in a disease-relevant tissue in 
vivo.  
DISCUSSION 
This work establishes GVs as the first genetically encodable 
nuclei for inertial cavitation, bringing together the unique 
capabilities of targeted therapeutics, synthetic biology, focused 
ultrasound and bubble mechanics. Our fundamental finding 
Figure 6 | Theranosic imaging and GV-seeded cavitation in in vivo tumor xenografts. a, Schematic drawing of in vivo FUS and 
imaging/PCD setup. A 670 kHz FUS transducer and a 18 MHz imaging linear array transducer are aligned using a 3D-printed cone holder. 
Balb/c mice harbor bilateral MC26 subcutaneous hind-limb tumor xenografts. b, Ultrasound images of tumors injected with engineered 
nonlinear GVs or saline (sham control). The grayscale B-mode images present the anatomy of the tumor, while amplitude modulation (AM) 
imaging shows GV-selective nonlinear contrast, which disappears after FUS application. c, Representative PCD spectra measured before and 
after injection of purified GVs (2.7 nM) or saline into tumors. Single 1.0 MPa, 30-cycle long pulses were transmitted from a 670 kHz FUS 
transducer. d, Relative broadband signal measured from pre- and post- GV and saline injections into tumors (p=0.002, n=4). Bar plots show 
mean ± SEM (d). Scale bar is 3 mm (b). 
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that GVs are capable of nucleating cavitation both in their 
purified form and inside genetically engineered cells will enable 
two distinct types of future applications. First, purified GVs 
targeted to cells such as tumors via specific surface markers can 
serve as ultrasound-triggered disruptors of the plasma 
membrane, causing cell death and making the interior of the 
target cells accessible to synergistic drug molecules. The 
development of this application will benefit from GVs’ 
fundamental physical stablitiy13, the tunability of their size and 
shape, and the ability of their surfaces to be functionalized via 
genetic fusion or chemical methods.  
Second, GVs expressed by engineered cells will 
provide a new capability for therapeutic synthetic biology. 
Compared to conventional drugs, cell-based therapeutic 
agents such as engineered bacteria have a broader range of 
functionality based on their ability to migrate to diseased 
tissues such as tumors2,3 or the GI tract7, recognize specific 
molecular signals, proliferate, and produce therapeutic 
biomolecules. Giving such agents the ability to express their 
own GVs as intracellular cavitation nuclei turns them into 
ultrasound-triggered cellular explosives, whose remote 
actuation results in the release of intracellular therapeutic 
payloads. In addition, the accompanying bacterial lysis may 
help activate the immune system32, thereby enhancing the 
efficacy of co-administered immunotherapy2,33. Furthermore, 
the ability of focused ultrasound to specify where and when in 
the body these effects take place could help overcome off-target 
toxicity arising from cell migration to organs such as the spleen, 
liver, and kidney34,35. Additionally, the conditional production 
of GVs in response to specific biochemical signals could add 
another layer of control.  
 The development of GVs as therapeutic agents will 
further benefit from their ability to be visualized with non-
invasive imaging modalities such as ultrasound and magnetic 
resonance imaging, allowing theranostic treatment planning 
and verification. The unique contrast produced by GVs can be 
combined with other imaging modes providing information 
about tissue features such as vascularization, oxygenation, and 
elasticity36–38. In this context, one of the important findings of 
this work is the clear distinction between the ultrasound 
frequencies and pressure levels needed for GV cavitation 
compared to those used for imaging. In addition, the 
disappearance of GV image contrast after cavitation provides 
a means to confirm the spatial targeting of therapeutic 
activation.  
The proof-of-concept experiments presented in this 
work establish the need for essential follow-up studies to further 
understand and apply the biomolecular acoustic cavitation 
paradigm. Higher-resolution optical imaging is needed to 
more fully visualize GV collapse, nanoscale bubble formation, 
growth and cavitation. Currently only GV collapse and 
micron-size bubble formation could be seen, and it was not 
possible to quantify the efficiency of each step in this overall 
process. Additional fundamental studies are also needed to 
characterize the impact of GV clustering at the cellular surface 
or interior, and of the surrounding biochemical composition, 
on bubble nucleation. Based on the insights from such studies, 
GVs and GV-expressing cells can be further engineered to 
increase their capabilities as cavitation nuclei. For example, 
genetic engineering allows the tuning of GV particle properties 
such as critical collapse pressures, dimensions, and surface 
chemistry19,31. GV-expressing cells can also be tuned to adjust 
expression levels for GVs and therapeutic payloads, the timing 
or conditional triggering of expression, and other cellular 
properties such as wall and membrane composition, which 
may influence cavitation and lysis. In addition, ongoing efforts 
to express GVs in mammalian cells will greatly expand the 
range of cellular sonotherapeutics. Finally, building on the 
fundamental findings and basic proof-of-concept 
demonstrations performed in this study, future work must test 
specific therapeutic applications in more sophisticated disease 
models. We expect the discovery of genetically encoded nuclei 
for inertial cavitation to produce an explosion of future studies 
and applications. 
 
MATERIALS AND METHODS 
Chemicals 
All chemicals were purchased from Sigma Aldrich unless 
otherwise noted. 
 
GV purification, modification, and quantification 
Anabaena flos-aquae GVs were produced and purified as 
described previously31. As a quality assurance step, OD 
measurements were performed for each sample at 0-12 bar 
using an echoVis Vis-NIR light source coupled with an STS-
VIS spectrometer (Ocean Optics), and a 176.700-QS sample 
chamber (Hellma Analytics). GvpC was removed from GVs 
used in the in vivo experiment to facilitate their ultrasound 
detection. GvpC was removed and replaced by an engineered, 
recombinantly expressed, protein, GvpC-RGD, for 
experiments in which GVs were attached to U87 cells19. This 
GvpC variant (GvpC-R3) was also shorter than the wild type 
protein, resulting in GV collapse at lower pressure levels19. 
Prior to experiments, GV concentrations were measured using 
a spectrophotometer (Thermo Scientific NanoDrop™ ND-
1000) at 500nm. 
 
In vitro passive cavitation detection 
The in vitro setup (Fig. 2a) was aligned in a three-step process. 
First, an L22-14v 128-element Verasonics imaging probe was 
positioned such that its focus, set to a depth of 8 mm, was at 
the center of a 1 cm x 1 cm 3D-printed chamber. Then, an 
optic fiber hydrophone (Precision Acoustics) was positioned at 
the center of the chamber using B-mode imaging. Finally, a 
670 kHz (Precision Acoustics) or 3 MHz FUS transducer 
(Ultrasonic S-Lab) was mounted on a computer-controlled 3D 
translatable stage (Velmex) orthogonally to the Verasonics 
probe. A MATLAB program automatically scanned and 
aligned the transducer’s focus at the center of the chamber, 
according to the feedback from the hydrophone. 
A solution of purified GVs (OD500 = 0.5, or 0.3 nM, 
unless stated differently) or GV-expressing bacteria (OD600 = 
1) was gently pipetted into the 3D printed chamber to 
minimize the introduction of bubbles. Purified GVs solutions 
had been prepared several days in advance to allow natural 
degassing to atmospheric conditions. The Verasonics scanner 
was programmed to function in zero-amplitude transmit so it 
could be used as a passive cavitation detector. A MATLAB 
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script was written to synchronize the acquisition of GV signals 
by triggering the FUS burst and accounting for the 
propagation time of the insonating wave to the focus. The GV 
solution was stirred gently during acquisition using a micro stir 
bar and magnetic stirrer (Thermo Scientific).  
To compensate for the slow rise time of the Precision 
Acoustics transducer, a custom waveform with 33 cycles was 
created such that the first 4 cycles had 1.5x the amplitude as 
the last 29 cycles; this waveform induced our FUS to reach the 
desired peak negative pressure (PNP) output at the 4th cycle. In 
experiments where the effect of the number of cycles on 
cavitation was investigated, a waveform with 3 cycles at 2x the 
amplitude of the remaining cycles was used so that the desired 
PNP was reached at the 3rd negative peak. 
 
Mammalian cells experiments 
Glass bottom 35-mm petri dishes (Matsunami) were modified 
to enable U87 cell culture and subsequent ultrasound 
application. The glass was removed using a glass cutter and 
Mylar film (Chemplex, 2.5 μM thickness) was fixed over the 
hole via a polydimethylsiloxane elastomer (Sylgard 184 
silicone, Dow Corning). After curing for 24 hours at 40°C, 
these dishes were sterilized using UV light. U87 cells were 
plated on the Mylar film dish and incubated for 2 days at 37°C 
in 2mL of DMEM media. In order to facilitate the attachment 
of RGD-GVs to the cells membrane, the GVs were re-
suspended in fresh DMEM (final concentration of 0.5 OD500) 
and added to the center of the dishes. The center of each dish 
was sealed using an 18-mm round cover glass and kept inverted 
for 2 hours at room temperature. Then, cells were washed and 
recovered with fresh DMEM. Finally, 10 μg/ml propidium 
iodide (PI, Invitrogen) was added to the medium just before the 
ultrasound experiment. 
In this experiment, the cells were insonated using a 
670 kHz transducer (Precision Acoustics) that was positioned 
in the water tank at an angle of 20° relative to the water 
surface, to minimize standing waves (Fig. 4a). The ultrasound 
transducer was aligned to the microscope using a hydrophone. 
The cells were insonated for 10 seconds with PNP = 1.5 MPa 
ultrasound pulses at a 2 ms pulse repetition rate.  Fluorescence 
recording began 1 minute before insonation, continued 
throughout ultrasound exposure, and ended 10 minutes after 
insonation. Fluorescence signals were collected using a 10x 
immersion objective (Olympus, NA 0.3), and a sCMOS 
camera (Zyla 5.5, Andor) at a 10 Hz frame rate. After this 
acquisition, we used saponin (Sigma, 100 μg/ml) to perforate 
all cell membranes, and the resulting image was used as a mask 
for cell body detection. The fluorescence images were 
processed using NeuroCa39 to extract fluorescent signals from 
individual cells. Cells were defined as PI-positive if signal 
intensity increased by more than 2% following ultrasound 
application. 
 
High frame rate camera imaging experiments 
We assembled a high-speed microscopy setup capable of 
directly capturing GV collapse and bubble cavitation events 
(Fig. 3a).  Our setup used a 2-W 532-nm laser (CNI, MLL-F-
532-2W) controlled by an optical beam shutter (Thorlabs 
SH05, KSC101). Right angle prism mirrors directed the laser 
light through a water bath and into a sample dish containing 
the imaged samples. For imaging purified GVs, the GVs were 
biotinylated by incubating them for 1 hour with a 10,000-fold 
molar excess of sulfo-NHS-biotin (Thermo Fisher Scientific). 
Then, the non-attached biotin was removed by dialysis in PBS. 
The Mylar dishes were prepared by first treating them with 
UV light, then incubating them with 180 µL of 0.1 mg/mL 
poly-D-lysine hydrobromide.  The dishes were then incubated 
with sulfo-NHS-biotin (Thermo Fisher Scientific, 180 µL, 
2mM) for 1 hour. After washing away free biotin with PBS, 
dishes were incubated with streptavidin (G-Biosciences, 180 
µL, 7.35µM) for 1 hour and washed again to remove unbound 
streptavidin. Finally, the biotinylated GVs were attached to the 
dishes. After adding 180 µL of GVs at OD500 = 2 to each dish, 
the center of each dish was sealed using an 18 mm round cover 
glass and kept inverted for 2 hours at room temperature. Then, 
excess GVs were washed away with PBS. All wash steps were 
repeated at least 3 times. For imaging cells, the same dishes and 
cell culture processes described in the previous section were 
used, except with a final GV concentration of OD500 = 2. 
Dishes containing GVs or cells were positioned above a water 
tank and aligned with the transducer focus as described above. 
A 10x water immersion Plan Fluor objective (Olympus, NA 
0.3) was lowered into the solution in the dish. A series of prism 
mirrors and converging lenses with focal lengths of 200 mm 
and 50 mm delivered the image into a Shimadzu HPV-X2 
camera, which acquired 256 images (Supplementary Fig. 
3) over 51.2 µs, at a sampling rate of 5 million frames per 
second.  To account for acoustic propagation through water, 
the camera was externally triggered to begin acquisition 40 µs 
after the start of the ultrasound pulse. A single pulse with 30 
cycles and PNP = 1.4 MPa was used to insonate the sample in 
these experiments. 
 
Bacterial expression and experiments  
GV-expressing Salmonella typhimurium were produced by 
transforming cells with a plasmid encoding an engineered 
genetic construct comprising a GV operon 15,31 and a NanoLuc 
luciferase. Cells transformed with a NanoLuc-only plasmid 
were used as controls. Constructs were assembled using Gibson 
cloning. The genetic constructs were cloned into the pTD103 
plasmid (gift from J. Hasty), with expression driven by a luxI 
promoter upon induction with 3nM N-(β-ketocaproyl)-l-
homoserine lactone (AHL). The cells were cultured for 24 
hours at 30 ⁰C after induction, then centrifugated for 4 hours 
at 150 x g and 4 ⁰C to enrich for buoyant cells.  Samples of cells 
used in PCD experiments were stored for two days at 4 ⁰C 
before these experiments and were always gently pipetted so as 
to minimize media gassing and bubble formation. Cells used 
for the NanoLuc release experiment were washed four times 
by 2 hours of centrifugation at 150 x g and 4 ⁰C to remove any 
NanoLuc molecules that may be present in the media prior to 
the experiment. 
PCD recordings from GV-expressing cells were 
performed using the same setup and protocol used in PCD 
recordings from purified GVs, with cells at a concentration of 
OD600 = 1. The same experimental setup was also used in the 
bacteria lysis and the payload release experiments; however, in 
these experiments, samples were insonated for 30 seconds at 
300 kHz, PNP = 1 MPa, and a pulse repetition interval of 2 
ms. In addition, to place the cell samples at the main lobe of 
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the ultrasound beam, the sample chamber was filled with 1% 
agar, leaving a 4 mm diameter empty well, located in its center. 
Cell samples were loaded into this well at a concentration of 
OD600 = 2 and a volume of 50 mL, and covered with paraffin 
oil. For colony counts, the cells were plated on agar plates with 
kanamycin. Plates were imaged using a ChemiDoc Gel 
Imaging System (Bio-Rad) using a white epi-illumination 
protocol. Then, the colonies were counted to determine total 
colony forming units. In the payload release experiments, the 
solution was aspirated from the chamber after exposure to 
ultrasound, pipetted into 100 kDa Spin-X(R) UF concentrators 
(Corning) and centrifuged at 300 x g for 30 minutes to separate 
the supernatant fluid from the pellet and the buoyant cells. 
Then, the NanoLuc signal was measured using a Nano-Glo 
Luciferase assay kit (Promega) and a plate reader system 
(molecular devices). Full chemical lysis of cells using 
SoluLyse™ Protein Extraction Reagent (Genlantis) was used 
as positive control. 
In vivo passive cavitation detection 
All in vivo experiments were performed on BALB/c female 
mice, under a protocol approved by the Institutional Animal 
Care and Use Committee of the California Institute of 
Technology. No randomization or blinding were necessary in 
this study. Mice were anaesthetized using 1–2.5% isoflurane 
during all the injection and imaging procedures. The MC26 
colorectal cancer cell line were maintained per standard cell 
culture techniques. Four female BALB/c mice, aged 8 weeks, 
were given subcutaneous inoculations of 5 × 106 MC26 cells 
into both right and left hind flanks. Tumors were monitored 
and permitted to grow to a diameter of 6-10 mm over 10-20 
days.  
A 3D-printed theranostic holder co-aligned a 0.67 
MHz FUS transducer (Precision Acoustics) and an L22-14v 
128-element imaging probe (Verasonics) by fixing the FUS 
focus at 12 mm along the imaging plane (Fig. 6a). The holder 
places the FUS cone facing downwards and the imaging probe 
at approximately 30° from the vertical. A 3D-printed needle 
guide was mounted to the side of the cone such that the tip of 
a 1-inch 30-gauge injection needle also intersected the focus. 
The holder was mounted on a manually-controlled 3D 
positioner.
Mice were anaesthetized, maintained at 37 °C on a 
heating pad, depilated over the tumor region, and positioned 
with tumor facing directly upwards. Prior to the experiment, 
the ultrasound gel was centrifugated at 2000 x g for 10 minutes 
to remove bubbles, heated to 37 °C, and then carefully applied 
to couple the cone and probe to the tumor. B-mode anatomical 
imaging was used to confirm the absence of bubbles in gel 
application and to position the center of the tumor at an axial 
depth of 12 mm. B-mode and amplitude modulation (AM)22 
images of the tumor were saved pre- and post-insonation. 
Insonation comprised a single 30-cycle, PNP = 1 MPa burst. 
The same PCD script was used as for in vitro PCD acquisitions. 
As part of the experiment, 20 μl of OD500 = 4.5 GVs 
(with GvpC removed) or saline were infused directly into the 
tumor at a flow rate of 10 μl min−1 via a Genie Touch syringe 
pump through PE10 catheter tubing and a 30-gauge needle 
(BD). Injection at the focal zone was confirmed via B-mode 
imaging by locating the needle tip, and AM and B-mode 
images were recorded pre- and post-insonation. PCD 
measurements were performed during each insonation. 
Passive cavitation detection data processing  
The acoustic emissions acquired by the PCD were sampled by 
the Verasonics scanner at 62.5 MHz and processed using a 
MATLAB (2017b, Mathworks) script. Single channel, 8192 -
point FFT frequency spectrum estimations of the RF 
recordings from the 128 transducer elements were averaged to 
produce each PCD frequency spectrum estimation. To 
calculate the average amount of stable cavitation, an 
acquisition with clear harmonic response was used to manually 
select and save the peak harmonic frequencies (see 
Supplementary Table 1). Then, a trend curve was fitted to 
each spectral estimation using the MATLAB Curve Fitting 
tool. The smoothing parameter was chosen such that the 
resulting curves included only the broadband signal and not 
any harmonic peaks. This smoothened curve was subtracted 
from the original frequency spectrum, and the resulting 
flattened spectrum with harmonic peaks was integrated over 
the peaks, each with a bandwidth of 191 kHz for the 670 kHz 
measurements, or 610 kHz for 3 MHz measurements (so as to 
include the full harmonic peak). Integrals were performed 
using trapezoidal sums, then the integral was divided by the 
product of the number of peaks and the peak bandwidth. 
To calculate the average amount of broadband 
emission, baseline noise at PNP = 0 MPa was subtracted from 
each reading. Then, the flattened spectrum with harmonic 
peaks was subtracted. The remaining spectrum was integrated 
between 7.4 MHz and 28.6 MHz, which marked the beginning 
and end of baseline noise, then divided by 21.2 MHz. 
Statistical analysis 
For statistical significance testing, we used two-sided 
heteroscedastic t-tests with a significance level of type I error 
set at 0.05 for rejecting the null hypothesis, unless mentioned 
otherwise. A Wilcoxon rank sum test was used in high-speed 
camera experiments that included a control group that was 
found to be non-Gaussian using a Lilliefors test (P < 0.001). A 
two-way ANOVA test was used in the payload release 
experiment. Sample sizes for all experiments, including animal 
experiments, were chosen on the basis of preliminary 
experiments to be adequate for statistical analysis. 
Data and code availability 
MATLAB codes are available from the corresponding author 
upon reasonable request. Plasmids sequences are included in 
Supplementary Information (Supplementary Table 2), and 
plasmids will be made available through Addgene upon 
publication. All other materials and data are available from the 
corresponding author upon reasonable request. 
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